Communiqués Alimera Sciences, Inc.

Actions

ALIM

US0162592028

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/09/2024			Varia. 5j.	Varia. 1 janv.
5,540 ^USD	-0,18%		-.--%	-

16/09/24	ANI Pharmaceuticals finalise l'achat d'Alimera Sciences, prévoit des bénéfices 'substantiellement plus élevés' après l'opération	MT
16/09/24	ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) a conclu l'acquisition d'Alimera Sciences, Inc. (NasdaqGM:ALIM) auprès de Caligan Partners Master Fund LP et Caligan Partners Master Fund LP, gérés par Caligan Partners, LP et d'autres.	CI

Communiqués

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU
20/08/24	ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM	BU
06/08/24	Alimera Sciences: Q2 Earnings Snapshot	AQ
06/08/24	Alimera Sciences Reports Second Quarter 2024 Results	AQ
29/06/24	ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM	BU
24/06/24	ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals	AQ
04/06/24	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
14/05/24	Alimera Sciences: Q1 Earnings Snapshot	AQ
14/05/24	Alimera Sciences Reports First Quarter 2024 Results	AQ
07/05/24	Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences	AQ
30/04/24	Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update	AQ
20/03/24	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
19/03/24	Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	AQ
07/03/24	Alimera Sciences: Q4 Earnings Snapshot	AQ
07/03/24	Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results	AQ
29/02/24	Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update	AQ
08/02/24	The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®	AQ
04/01/24	Alimera Completes Recruitment for the Synchronicity Study	AQ
02/01/24	Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/12/23	Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
08/11/23	Alimera Appoints Maggie A. Pax to Its Board of Directors	AQ
31/10/23	Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology	AQ